Efficient polarization entanglement purification based on parametric down-conversion sources with cross-Kerr nonlinearity

We present a way for entanglement purification based on two parametric down-conversion (PDC) sources with cross-Kerr nonlinearities. It is comprised of two processes. The first one is a primary entanglement purification protocol for PDC sources with nondestructive quantum nondemolition (QND) detectors by transferring the spatial entanglement of photon pairs to their polarization. In this time, the QND detectors act as the role of controlled-not (CNot) gates. Also they can distinguish the photon number of the spatial modes, which provides a good way for the next process to purify the entanglement of the photon pairs kept more. In the second process for entanglement purification, new QND detectors are designed to act as the role of CNot gates. This protocol has the advantage of high yield and it requires neither CNot gates based on linear optical elements nor sophisticated single-photon detectors, which makes it more convenient in practical applications.Comment: 8 pages, 7 figure

Charged lepton flavor violating Higgs decays at future e+e−e^+e^- colliders

After the discovery of the Higgs boson, several future experiments have been proposed to study the Higgs boson properties, including two circular lepton colliders, the CEPC and the FCC-ee, and one linear lepton collider, the ILC. We evaluate the precision reach of these colliders in measuring the branching ratios of the charged lepton flavor violating Higgs decays $H\to e^\pm\mu^\mp$, $e^\pm\tau^\mp$ and $\mu^\pm\tau^\mp$. The expected upper bounds on the branching ratios given by the circular (linear) colliders are found to be $\mathcal{B}(H\to e^\pm\mu^\mp) < 1.2\ (2.1) \times 10^{-5}$, $\mathcal{B}(H\to e^\pm\tau^\mp) < 1.6\ (2.4) \times 10^{-4}$ and $\mathcal{B}(H\to \mu^\pm\tau^\mp) < 1.4\ (2.3) \times 10^{-4}$ at 95\% CL, which are improved by one to two orders compared to the current experimental bounds. We also discuss the constraints that these upper bounds set on certain theory parameters, including the charged lepton flavor violating Higgs couplings, the corresponding parameters in the type-III 2HDM, and the new physics cut-off scales in the SMEFT, in RS models and in models with heavy neutrinos.Comment: 20 pages, 2 figures (extend the CEPC study to the FCC-ee and the ILC, and to match the published version

Multipartite entanglement purification with quantum nondemolition detectors

We present a scheme for multipartite entanglement purification of quantum systems in a Greenberger-Horne-Zeilinger state with quantum nondemolition detectors (QNDs). This scheme does not require the controlled-not gates which cannot be implemented perfectly with linear optical elements at present, but QNDs based on cross-Kerr nonlinearities. It works with two steps, i.e., the bit-flipping error correction and the phase-flipping error correction. These two steps can be iterated perfectly with parity checks and simple single-photon measurements. This scheme does not require the parties to possess sophisticated single photon detectors. These features maybe make this scheme more efficient and feasible than others in practical applications.Comment: 8 pages, 5 figure

Plasmacytoid Dendritic Cells and Cancer Immunotherapy

Despite largely disappointing clinical trials of dendritic cell (DC)-based vaccines, recent studies have shown that DC-mediated cross-priming plays a critical role in generating anti-tumor CD8 T cell immunity and regulating anti-tumor efficacy of immunotherapies. These new findings thus support further development and refinement of DC-based vaccines as mono-immunotherapy or combinational immunotherapies. One exciting development is recent clinical studies with naturally circulating DCs including plasmacytoid DCs (pDCs). pDC vaccines were particularly intriguing, as pDCs are generally presumed to play a negative role in regulating T cell responses in tumors. Similarly, DC-derived exosomes (DCexos) have been heralded as cell-free therapeutic cancer vaccines that are potentially superior to DC vaccines in overcoming tumor-mediated immunosuppression, although DCexo clinical trials have not led to expected clinical outcomes. Using a pDC-targeted vaccine model, we have recently reported that pDCs required type 1 conventional DCs (cDC1s) for optimal cross-priming by transferring antigens through pDC-derived exosomes (pDCexos), which also cross-prime CD8 T cells in a bystander cDC-dependent manner. Thus, pDCexos could combine the advantages of both cDC1s and pDCs as cancer vaccines to achieve better anti-tumor efficacy. In this review, we will focus on the pDC-based cancer vaccines and discuss potential clinical application of pDCexos in cancer immunotherapy